Plus   Neg

Mirum Pharma Surges 190% In 3 Days

europeanstock2 dec16 18dec19 lt

Mirum Pharmaceuticals Inc. (MIRM), which topped the list of Biggest Percentage Price Gainers among healthcare stocks on Monday, topped the list again on Wednesday - gaining 44% to close at an all-time high of $23.76, before touching an intraday high $27.28.

On Monday, the Company had announced that a pre-NDA meeting with the FDA for Maralixibat was successful.

Maralixibat has been evaluated in a long-term phase IIb study in Alagille syndrome, dubbed ICONIC, and updated results were presented in April of this year. The study demonstrated that Maralixibat treatment led to a profound and durable improvement in pruritis, xanthomas (lipid accumulation in the skin) and bile acids over 48 weeks.

Following the successful discussions with the FDA, the Company is planning a rolling NDA submission for Maralixibat in Alagille syndrome, which will be initiated in the third quarter of 2020.

Mirum licensed Maralixibat from Shire last November.

Based on Wednesday's closing price of $23.76, Mirum shares have gained an impressive 190% in just three days.

Related Reading

From $7 To $22: Did Mirum Pharma's ICONIC Jump Make Big Money For You?

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT